CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

CSPC Pharmaceutical starts Phase I/II trial of SYS6062 for advanced solid tumors in China

By Public Technologies
  • CSPC Pharmaceutical Group announced Nov. 5, 2026, the launch of its Phase I/II SYS6062 trial for advanced solid tumors in China.
  • The first-in-human study follows Chinese regulatory clearance in October 2026. Participant recruitment and screening are underway.
  • SYS6062 is an antibody-drug conjugate targeting CEACAM5, designed to kill tumor cells and surrounding cancer cells.
  • The multicenter trial will assess safety, tolerability and preliminary antitumor activity, alongside how the drug behaves in the body.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261105-12402543), on November 05, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk